Contact
searchSearch
HMP Global
Login

Desmoid Tumors

Desmoid Tumors
Specialty Channel
News
Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Patients With Advanced Desmoid Tumors
10/09/2026
Emily Estrada
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial...
10/09/2026
Oncology
Quiz
Nirogacestat in Young Adult Patients With Desmoid Tumors
10/08/2026
Test your knowledge of real-world outcomes with nirogacestat in young adults with desmoid tumors, including disease control, symptom improvement, and treatment-related toxicity observed in a retrospective, single-institution study.
Test your knowledge of real-world outcomes with nirogacestat in young adults with desmoid tumors, including disease control, symptom improvement, and treatment-related toxicity observed in a retrospective, single-institution study.
Test your knowledge of...
10/08/2026
Oncology
News
MRI-Adapted M-RECIST Better Characterizes Treatment Response After Cryoablation in Desmoid-Type Fibromatosis
09/14/2026
Emily Estrada
MRI-adapted M-RECIST identified more complete and partial responses than conventional RECIST following percutaneous cryoablation for progressing extra-abdominal desmoid-type fibromatosis, supporting viability-based imaging as a potentially...
MRI-adapted M-RECIST identified more complete and partial responses than conventional RECIST following percutaneous cryoablation for progressing extra-abdominal desmoid-type fibromatosis, supporting viability-based imaging as a potentially...
MRI-adapted M-RECIST identified...
09/14/2026
Oncology
News
Real-World Study Shows Nirogacestat Provides Sustained Disease Control and Symptom Improvement in Patients With Desmoid Tumors
08/31/2026
Emily Estrada
A real-world study of nirogacestat in patients with desmoid tumors demonstrated durable disease control, tumor responses, and meaningful pain improvement, with many patients also reducing or discontinuing analgesics, reinforcing the clinical...
A real-world study of nirogacestat in patients with desmoid tumors demonstrated durable disease control, tumor responses, and meaningful pain improvement, with many patients also reducing or discontinuing analgesics, reinforcing the clinical...
A real-world study of...
08/31/2026
Oncology
News
Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors
07/28/2026
Emily Estrada
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that...
07/28/2026
Oncology
News
Real-World Study Highlights Evolving Treatment Patterns and Persistent Diagnostic Challenges in Patients With Desmoid Tumors
07/28/2026
Emily Estrada
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated...
07/28/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors
07/09/2026
Emily Estrada
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug...
07/09/2026
Oncology
News
Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Patients With Progressive Desmoid Tumors
07/06/2026
Emily Estrada
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly improved progression-free survival and objective response rate compared with placebo in patients with progressive or symptomatic desmoid tumors,...
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly improved progression-free survival and objective response rate compared with placebo in patients with progressive or symptomatic desmoid tumors,...
Results from a phase 3 trial...
07/06/2026
Oncology
News
M-RECIST Improves Response Assessment Following Cryoablation in Extra-Abdominal Desmoid-Type Fibromatosis
07/06/2026
Emily Estrada
Results from a retrospective study demonstrated that MRI-adapted RECIST identified substantially higher response rates than RECIST 1.1 following percutaneous cryoablation in patients with progressing extra-abdominal desmoid-type fibromatosis,...
Results from a retrospective study demonstrated that MRI-adapted RECIST identified substantially higher response rates than RECIST 1.1 following percutaneous cryoablation in patients with progressing extra-abdominal desmoid-type fibromatosis,...
Results from a retrospective...
07/06/2026
Oncology
Quiz
Progression-Free Survival Outcomes With Pegylated Liposomal Doxorubicin in Patients With Desmoid Tumors
06/19/2026
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated...
06/19/2026
Oncology
News
Varegacestat Demonstrates Strong Clinical Promise in Patients With Desmoid Tumors
06/08/2026
Emily Estrada
Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.
Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.
Results from the phase 3...
06/08/2026
Oncology

News

News
Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Patients With Advanced Desmoid Tumors
10/09/2026
Emily Estrada
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial...
10/09/2026
Oncology
News
MRI-Adapted M-RECIST Better Characterizes Treatment Response After Cryoablation in Desmoid-Type Fibromatosis
09/14/2026
Emily Estrada
MRI-adapted M-RECIST identified more complete and partial responses than conventional RECIST following percutaneous cryoablation for progressing extra-abdominal desmoid-type fibromatosis, supporting viability-based imaging as a potentially...
MRI-adapted M-RECIST identified more complete and partial responses than conventional RECIST following percutaneous cryoablation for progressing extra-abdominal desmoid-type fibromatosis, supporting viability-based imaging as a potentially...
MRI-adapted M-RECIST identified...
09/14/2026
Oncology
News
Real-World Study Shows Nirogacestat Provides Sustained Disease Control and Symptom Improvement in Patients With Desmoid Tumors
08/31/2026
Emily Estrada
A real-world study of nirogacestat in patients with desmoid tumors demonstrated durable disease control, tumor responses, and meaningful pain improvement, with many patients also reducing or discontinuing analgesics, reinforcing the clinical...
A real-world study of nirogacestat in patients with desmoid tumors demonstrated durable disease control, tumor responses, and meaningful pain improvement, with many patients also reducing or discontinuing analgesics, reinforcing the clinical...
A real-world study of...
08/31/2026
Oncology
News
Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors
07/28/2026
Emily Estrada
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that...
07/28/2026
Oncology
News
Real-World Study Highlights Evolving Treatment Patterns and Persistent Diagnostic Challenges in Patients With Desmoid Tumors
07/28/2026
Emily Estrada
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated...
07/28/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors
07/09/2026
Emily Estrada
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug...
07/09/2026
Oncology
News
Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Patients With Progressive Desmoid Tumors
07/06/2026
Emily Estrada
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly improved progression-free survival and objective response rate compared with placebo in patients with progressive or symptomatic desmoid tumors,...
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly improved progression-free survival and objective response rate compared with placebo in patients with progressive or symptomatic desmoid tumors,...
Results from a phase 3 trial...
07/06/2026
Oncology
News
M-RECIST Improves Response Assessment Following Cryoablation in Extra-Abdominal Desmoid-Type Fibromatosis
07/06/2026
Emily Estrada
Results from a retrospective study demonstrated that MRI-adapted RECIST identified substantially higher response rates than RECIST 1.1 following percutaneous cryoablation in patients with progressing extra-abdominal desmoid-type fibromatosis,...
Results from a retrospective study demonstrated that MRI-adapted RECIST identified substantially higher response rates than RECIST 1.1 following percutaneous cryoablation in patients with progressing extra-abdominal desmoid-type fibromatosis,...
Results from a retrospective...
07/06/2026
Oncology
News
Varegacestat Demonstrates Strong Clinical Promise in Patients With Desmoid Tumors
06/08/2026
Emily Estrada
Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.
Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.
Results from the phase 3...
06/08/2026
Oncology
News
Nirogacestat Demonstrates Encouraging Real-World Activity in Patients With Desmoid Tumors
06/08/2026
Emily Estrada
Results from a retrospective real-world analysis demonstrated that nirogacestat improved response compared to other commonly used systemic therapies in patients with desmoid tumors.
Results from a retrospective real-world analysis demonstrated that nirogacestat improved response compared to other commonly used systemic therapies in patients with desmoid tumors.
Results from a retrospective...
06/08/2026
Oncology

Interactive Features

Quiz
Nirogacestat in Young Adult Patients With Desmoid Tumors
10/08/2026
Test your knowledge of real-world outcomes with nirogacestat in young adults with desmoid tumors, including disease control, symptom improvement, and treatment-related toxicity observed in a retrospective, single-institution study.
Test your knowledge of real-world outcomes with nirogacestat in young adults with desmoid tumors, including disease control, symptom improvement, and treatment-related toxicity observed in a retrospective, single-institution study.
Test your knowledge of...
10/08/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors
07/09/2026
Emily Estrada
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug...
07/09/2026
Oncology
Quiz
Progression-Free Survival Outcomes With Pegylated Liposomal Doxorubicin in Patients With Desmoid Tumors
06/19/2026
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated liposomal doxorubicin (PLD) on progression-free survival compared with placebo in patients with advanced or refractory desmoid tumors?
What was the effect of pegylated...
06/19/2026
Oncology

Recent News

News
Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Patients With Advanced Desmoid Tumors
10/09/2026
Emily Estrada
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial...
10/09/2026
Oncology
News
MRI-Adapted M-RECIST Better Characterizes Treatment Response After Cryoablation in Desmoid-Type Fibromatosis
09/14/2026
Emily Estrada
MRI-adapted M-RECIST identified more complete and partial responses than conventional RECIST following percutaneous cryoablation for progressing extra-abdominal desmoid-type fibromatosis, supporting viability-based imaging as a potentially...
MRI-adapted M-RECIST identified more complete and partial responses than conventional RECIST following percutaneous cryoablation for progressing extra-abdominal desmoid-type fibromatosis, supporting viability-based imaging as a potentially...
MRI-adapted M-RECIST identified...
09/14/2026
Oncology
News
Real-World Study Shows Nirogacestat Provides Sustained Disease Control and Symptom Improvement in Patients With Desmoid Tumors
08/31/2026
Emily Estrada
A real-world study of nirogacestat in patients with desmoid tumors demonstrated durable disease control, tumor responses, and meaningful pain improvement, with many patients also reducing or discontinuing analgesics, reinforcing the clinical...
A real-world study of nirogacestat in patients with desmoid tumors demonstrated durable disease control, tumor responses, and meaningful pain improvement, with many patients also reducing or discontinuing analgesics, reinforcing the clinical...
A real-world study of...
08/31/2026
Oncology
News
Real-World Study Demonstrates Rapid Pain Relief, Durable Disease Control, and Manageable Safety With Nirogacestat in Young Adults With Desmoid Tumors
07/28/2026
Emily Estrada
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that nirogacestat provided rapid pain relief, durable disease control, and a manageable safety profile in young adults with desmoid tumors, supporting its use in routine clinical practice while emphasizing the...
A real-world study found that...
07/28/2026
Oncology
News
Real-World Study Highlights Evolving Treatment Patterns and Persistent Diagnostic Challenges in Patients With Desmoid Tumors
07/28/2026
Emily Estrada
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated declining use of surgery and increasing adoption of systemic therapies for desmoid tumors, while highlighting substantial symptom burden, frequent treatment changes, and increased healthcare resource...
Real-world findings demonstrated...
07/28/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Varegacestat in Adult Patients With Progressing Desmoid Tumors
07/09/2026
Emily Estrada
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug application for varegacestat for adults with progressing desmoid tumors following positive results from the phase 3 RINGSIDE trial, supporting the investigational oral gamma secretase inhibitor as a potential new...
The FDA accepted the new drug...
07/09/2026
Oncology
News
Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Patients With Progressive Desmoid Tumors
07/06/2026
Emily Estrada
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly improved progression-free survival and objective response rate compared with placebo in patients with progressive or symptomatic desmoid tumors,...
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly improved progression-free survival and objective response rate compared with placebo in patients with progressive or symptomatic desmoid tumors,...
Results from a phase 3 trial...
07/06/2026
Oncology
News
M-RECIST Improves Response Assessment Following Cryoablation in Extra-Abdominal Desmoid-Type Fibromatosis
07/06/2026
Emily Estrada
Results from a retrospective study demonstrated that MRI-adapted RECIST identified substantially higher response rates than RECIST 1.1 following percutaneous cryoablation in patients with progressing extra-abdominal desmoid-type fibromatosis,...
Results from a retrospective study demonstrated that MRI-adapted RECIST identified substantially higher response rates than RECIST 1.1 following percutaneous cryoablation in patients with progressing extra-abdominal desmoid-type fibromatosis,...
Results from a retrospective...
07/06/2026
Oncology
News
Varegacestat Demonstrates Strong Clinical Promise in Patients With Desmoid Tumors
06/08/2026
Emily Estrada
Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.
Results from the phase 3 RINGSIDE trial demonstrated that varegacestat significantly improved outcomes compared with placebo in patients with progressive desmoid tumors.
Results from the phase 3...
06/08/2026
Oncology
News
Nirogacestat Demonstrates Encouraging Real-World Activity in Patients With Desmoid Tumors
06/08/2026
Emily Estrada
Results from a retrospective real-world analysis demonstrated that nirogacestat improved response compared to other commonly used systemic therapies in patients with desmoid tumors.
Results from a retrospective real-world analysis demonstrated that nirogacestat improved response compared to other commonly used systemic therapies in patients with desmoid tumors.
Results from a retrospective...
06/08/2026
Oncology
FDA Approval
FDA Expands Nogapendekin Alfa Inbakicept Plus Bacillus Calmette-Guérin Approval to Include High-Grade Papillary-Only Bladder Cancer
10/14/2026
Emily Estrada
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication for nogapendekin alfa inbakicept plus Bacillus Calmette-Guérin (BCG) to include patients with high-grade papillary-only, BCG-unresponsive non-muscle-invasive bladder cancer, extending treatment eligibility...
The FDA expanded the indication...
10/14/2026
Oncology
News
Pegylated Liposomal Doxorubicin Improves Progression-Free Survival in Patients With Advanced Desmoid Tumors
10/09/2026
Emily Estrada
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged progression-free survival and objective response compared with placebo in patients with advanced or refractory desmoid tumors, supporting...
Results from a phase 3 trial...
10/09/2026
Oncology
News
Iberdomide Plus Daratumumab and Dexamethasone Significantly Improves PFS in Relapsed or Refractory Multiple Myeloma
10/08/2026
Stephanie Holland
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3 EXCALIBER-RRMM trial demonstrated significantly prolonged progression-free survival with iberdomide plus daratumumab and dexamethasone compared with daratumumab, bortezomib, and dexamethasone in...
Topline results from the phase 3...
10/08/2026
Oncology
News
Cytarabine Induction Followed by Azacitidine and Lenalidomide Shows Activity in Very-High-Risk Myelodysplastic Syndromes
10/08/2026
Emily Estrada
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study evaluating a resource-adapted treatment strategy for very-high-risk myelodysplastic syndromes demonstrated responses with cytarabine induction followed by azacitidine and lenalidomide, supporting further...
Results from a small study...
10/08/2026
Oncology
News
Acute Myeloid Leukemia Transformation Emerges as Strongest Predictor of Relapse After Allogenic-HSCT in Myelodysplastic Syndromes
10/08/2026
Emily Estrada
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of patients with myelodysplastic syndromes undergoing allogenic hematopoietic stem cell transplantation identified acute myeloid leukemia transformation as the strongest independent predictor of post-transplant...
A retrospective analysis of...
10/08/2026
Oncology
News
Epcoritamab Plus R-CHOP Improves Progression-Free Survival Over R-CHOP Alone in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma
10/08/2026
Emily Estrada
Topline results from the phase 3 EPCORE DLBCL-2 trial demonstrated that adding epcoritamab to R-CHOP significantly improved progression-free survival in newly diagnosed patients with diffuse large B-cell lymphoma, providing phase 3 evidence...
Topline results from the phase 3 EPCORE DLBCL-2 trial demonstrated that adding epcoritamab to R-CHOP significantly improved progression-free survival in newly diagnosed patients with diffuse large B-cell lymphoma, providing phase 3 evidence...
Topline results from the phase 3...
10/08/2026
Oncology
News
SurVaxM Shows Survival Signal in Newly Diagnosed Glioblastoma, With Significant Benefit in Younger Patients
10/07/2026
Emily Estrada
Results from the phase 2b SURVIVE trial showed a numerical overall survival improvement with SurVaxM in newly diagnosed patients with glioblastoma that did not reach statistical significance, while a prespecified subgroup of patients aged 65...
Results from the phase 2b SURVIVE trial showed a numerical overall survival improvement with SurVaxM in newly diagnosed patients with glioblastoma that did not reach statistical significance, while a prespecified subgroup of patients aged 65...
Results from the phase 2b...
10/07/2026
Oncology
FDA Approval
FDA Approves Tucatinib Plus Trastuzumab and Pertuzumab for Maintenance Treatment of HER2-Positive Advanced Breast Cancer
10/07/2026
Stephanie Holland
Based on results from the HER2CLIMB-05 trial, the FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance treatment for HER2-positive advanced breast cancer following induction therapy, establishing a new maintenance option...
Based on results from the HER2CLIMB-05 trial, the FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance treatment for HER2-positive advanced breast cancer following induction therapy, establishing a new maintenance option...
Based on results from the...
10/07/2026
Oncology
FDA Approval
FDA Expands Pirtobrutinib to First-Line Treatment of CLL/SLL Without 17p Deletion
10/02/2026
Stephanie Holland
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN CLL-313, the FDA approved pirtobrutinib for previously untreated CLL/SLL without a known 17p deletion, establishing a first-line treatment option supported by a significant progression-free survival benefit over...
Based on results from BRUIN...
10/02/2026
Oncology
News
Risvutatug Rezetecan More Than Doubles Response and Significantly Extends Survival in Patients With Relapsed Small Cell Lung Cancer
09/29/2026
Emily Estrada
Results from the phase 3 ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly improved overall and progression-free survival and response outcomes compared with topotecan in patients with small cell lung cancer who...
Results from the phase 3 ARTEMIS-008 trial demonstrated that risvutatug rezetecan significantly improved overall and progression-free survival and response outcomes compared with topotecan in patients with small cell lung cancer who...
Results from the phase 3...
09/29/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use